Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

61. Coexistence of seizure with Wilson's disease: a systematic review Full Text available with Trip Pro

may be the initial neurological symptom in approximately 10% of patients with WD, several case series fail to mention the seizures. Although some authors mention a number of WD cases with seizures, no further details regarding seizures were discussed. A few cases may have had both disorders, but there was doubt regarding the diagnosis of WD, or of epilepsy or both disorders. Method We followed the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA statement) guidelines (...) Partial SE Hypocupremia due to de‐coppering therapy Diffuse slowing and multifocal left temporo‐parieto‐occipital and right Centro‐frontal epileptiform activity Knight et al. 2009 case report 55 M 1 1 Parkinsonian features Non‐convulsive SE Tetrathiomolyb‐date therapy Normal ¥ Panagariya et al. 2007 case report __ __ 21 8 Multiple movement disorders and cognition Not reported __ Not reported Huang and N S, 1995 case report 23(3) M=2 F=1 3 3 Psychiatric symptoms, cerebral WML Focal seizures ± secondary

2020 Progress in Neurology and Psychiatry

62. Losigamone add-on therapy for focal epilepsy. Full Text available with Trip Pro

Losigamone add-on therapy for focal epilepsy. Epilepsy is a common neurologic disorder, affecting approximately 50 million people worldwide; nearly a third of these people have epilepsy that is not well controlled by a single antiepileptic drug (AED) and they usually require treatment with a combination of two or more AEDs. In recent years, many newer AEDs have been investigated as add-on therapy for focal epilepsy; losigamone is one of these drugs and is the focus of this systematic review (...) and seizure freedom; the secondary outcomes were treatment withdrawal and adverse events. Results are presented as risk ratios (RRs) with 95% confidence intervals (CIs) or 99% CIs (for the individual listed adverse events to make an allowance for multiple testing).Two studies involving a total of 467 participants, aged over 18 years, were eligible for inclusion. Both studies assessed losigamone 1200 mg/day or 1500 mg/day as an add-on therapy for focal epilepsy. We assessed one study as being of good

2019 Cochrane

63. Intravenous immunoglobulins for epilepsy. Full Text available with Trip Pro

for epilepsy management. This is an update of a Cochrane review first published in 2011 and last updated in 2017.To examine the effects of IVIg on the frequency and duration of seizures, quality of life and adverse effects when used as monotherapy or as add-on treatment for people with epilepsy.For the latest update, we searched the Cochrane Register of Studies (CRS Web) (20 December 2018), MEDLINE (Ovid, 1946 to 20 December 2018), Web of Science (1898 to 20 December 2018), ISRCTN registry (20 December (...) seizure-free, 50% or greater reduction in seizure frequency, adverse effects, treatment withdrawal and quality of life.We included one study (61 participants). The included study was a randomised, double-blind, placebo-controlled, multicentre trial which compared the treatment efficacy of IVIg as an add-on with a placebo add-on in patients with drug-resistant epilepsy. Seizure freedom was not reported in the study. There was no significant difference between IVIg and placebo in 50% or greater

2019 Cochrane

64. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial (Abstract)

Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial More than a third of patients with epilepsy are treatment resistant, and thus new, more effective therapies to achieve seizure freedom are needed. Cenobamate (YKP3089), an investigational antiepileptic drug, has shown broad-spectrum anticonvulsant activity in preclinical studies and seizure models. We aimed (...) to evaluate the safety, efficacy, and tolerability of adjunctive cenobamate in patients with uncontrolled focal (partial)-onset epilepsy.We did a multicentre, double-blind, randomised, placebo-controlled, dose-response study at 107 epilepsy and neurology centres in 16 countries. Adult patients (aged 18-70 years) with focal seizures despite treatment with 1-3 antiepileptic drugs were randomly assigned (1:1:1:1) via an interactive web response system, by block sizes of 4 within each country, to adjuvant

2019 EvidenceUpdates

65. Evaluation of Long-term Risk of Epilepsy, Psychiatric Disorders, and Mortality Among Children With Recurrent Febrile Seizures: A National Cohort Study in Denmark Full Text available with Trip Pro

Evaluation of Long-term Risk of Epilepsy, Psychiatric Disorders, and Mortality Among Children With Recurrent Febrile Seizures: A National Cohort Study in Denmark Febrile seizures occur in 2% to 5% of children between the ages of 3 months and 5 years. Many affected children experience recurrent febrile seizures. However, little is known about the association between recurrent febrile seizures and subsequent prognosis.To estimate the risk of recurrent febrile seizures and whether (...) there is an association over long-term follow-up between recurrent febrile seizures and epilepsy, psychiatric disorders, and death in a large, nationwide, population-based cohort in Denmark.This population-based cohort study evaluated data from all singleton children born in Denmark between January 1, 1977, and December 31, 2011, who were identified through the Danish Civil Registration System. Children born in Denmark who were alive and residing in Denmark at age 3 months were included (N = 2 103 232). The study

2019 EvidenceUpdates

66. Levetiracetam is a useful alternative to phenytoin for epileptic seizures in children. (Abstract)

Levetiracetam is a useful alternative to phenytoin for epileptic seizures in children. The studyLyttle MD, Rainford NEA, Gamble C, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet 2019;393:2125-34.This trial was funded by the NIHR Health Technology Assessment Programme (project number 12/127/134).To read the full NIHR Signal, go to https://discover.dc.nihr.ac.uk/content (...) /signal-000790/levetiracetam-vs-phenytoin-in-stopping-childrens-prolonged-epileptic-seizures.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

2019 BMJ

68. Neonatal seizures

• A range of genetic disorders causing epilepsy syndromes e.g. early onset epileptic encephalopathy; Ohtahara syndrome Developmental/ congenital • Abnormality of brain development 8 Queensland Clinical Guideline: Neonatal seizures Refer to online version, destroy printed copies after use Page 11 of 32 2.3 Presentation Neonatal seizures evolve over time. The peak incidence occurs between 12 and 24 hours of age but the time of onset is dependent on aetiology and treatment. Often the seizures cease by 72 (...) maintenance treatment for genetic and metabolic disorders usually lifelong 42,57 • Treatment usually continued if there is known progress to epilepsy (e.g. structural brain malformations and neonatal epilepsy syndromes) Queensland Clinical Guideline: Neonatal seizures Refer to online version, destroy printed copies after use Page 20 of 32 6.1 Anti-epileptic drugs 6.1.1 Phenobarbital Table 14. Phenobarbital Phenobarbital* Dose and administration • First line treatment • May be diluted to 10 mg/mL in 0.9

2019 Queensland Health

70. Topiramate add-on therapy for drug-resistant focal epilepsy. Full Text available with Trip Pro

Topiramate add-on therapy for drug-resistant focal epilepsy. The majority of people with epilepsy have a good prognosis and their seizures are controlled by a single antiepileptic drug. However, up to 20% of patients from population-based studies, and up to 30% from clinical series (not population-based), develop drug-resistant epilepsy, especially those with focal-onset seizures. In this review, we summarise the current evidence regarding topiramate, an antiepileptic drug first marketed (...) -on treatment for drug-resistant focal epilepsy as it is almost three times more effective compared to a placebo in reducing seizures. The trials reviewed were of relatively short duration and provided no evidence for the long-term efficacy of topiramate. Short-term use of add-on topiramate was shown to be associated with several adverse events. The results of this review should only be applied to adult populations as only one study included children. Future research should consider further examining

2019 Cochrane

71. Clobazam add-on therapy for drug-resistant epilepsy. Full Text available with Trip Pro

Clobazam add-on therapy for drug-resistant epilepsy. Epilepsy affects approximately 1% of the population, with up to 30% of patients continuing to have seizures, despite antiepileptic drug treatment. Clobazam is a 1,5-benzodiazepine and is commonly used as an add-on treatment for drug-resistant epilepsy. This review is an updated version of the original Cochrane Review, first published in 2008, and examines the most current literature regarding clobazam as an add-on for drug-resistant (...) epilepsy.To assess the efficacy, effectiveness and tolerability of clobazam as an add-on therapy for drug-resistant generalised-onset and focal-onset seizures, with or without secondary generalisation, in adults and children.For the latest update, we searched the following databases on 9 October 2018: Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL), Medline (Ovid) 1946 to 8 October

2019 Cochrane

72. Genetics in epilepsy, Dravet and SUDEP: A systematic review Full Text available with Trip Pro

genes disorders and its bibliographical references. SCN1A appears in three (3) different articles and locus. The gene mutations are linked to the pathologies: early infantile epileptic encephalopathy type 6 and generalized epilepsy with febrile seizures plus type 2. SCN9A is also related to Dravet Syndrome, and is associated to paroxysmal extreme pain disorder. Gene Locus Sudep Other disorders Reference SCN1A 2q24.3 YES Early Infantile Epileptic Encephalopathy type 6 and Generalized Epilepsy (...) with Febrile Seizures Plus type 2 12 SCN1A c.4507G>A p(E1503K) YES Early Infantile Epileptic Encephalopathy type 6 and Generalized Epilepsy with Febrile Seizures Plus type 2 13 SCN1A -- YES Early Infantile Epileptic Encephalopathy type 6 and Generalized Epilepsy with Febrile Seizures Plus type 2_ 14 SCN9A 2q24.3 YES Paroxysmal Extreme Pain Disorder 13 Table 1 Dravet syndrome The following presents microRNAs associated to Epilepsy. Only five (5) articles and nineteen (19) microRNA were found to be related

2019 Journal of Neurology & Stroke

73. Tiagabine add-on therapy for drug-resistant focal epilepsy. Full Text available with Trip Pro

and tremor, as low certainty.Tiagabine reduced seizure frequency but was associated with some adverse effects when used as an add-on treatment in people with drug-resistant focal epilepsy. The findings of the current review are mainly applicable to adults and adolescents, and may not necessarily be applicable to children as none of the trials included participants aged under 12 years. We found no significant differences between tiagabine and topiramate as add-on drugs; however, evidence was provided (...) Tiagabine add-on therapy for drug-resistant focal epilepsy. Epilepsy is a common neurological condition that affects up to 1% of the population. Nearly 30% of people with epilepsy are resistant to currently available antiepileptic drugs (AEDs) and require treatment with multiple antiepileptic drugs in combination. Tiagabine is one of the newer AEDs that can be used as an adjunct (add-on) to standard AEDs.To evaluate the efficacy and tolerability of tiagabine when used as an add-on treatment

2019 Cochrane

74. Antiepileptic drugs for seizure control in people with neurocysticercosis. Full Text available with Trip Pro

Antiepileptic drugs for seizure control in people with neurocysticercosis. Neurocysticercosis is the most common parasitic infection of the brain. Epilepsy is the most common clinical presentation, though it may also present with headache, symptoms of raised intracranial pressure, hydrocephalus and ocular symptoms depending upon the localisation of the parasitic cysts. Anthelmintic drugs, anti-oedema drugs, such as steroids, and antiepileptic drugs (AEDs) form the mainstay of treatment.This (...) have had at least one seizure due to neurocysticercosis.As part of primary prevention studies, we also aimed to examine which AED has been found to be beneficial in people with neurocysticercosis in terms of duration, dose and side-effect profile.For the latest update of this review, we searched the following databases on 8 July 2019: Cochrane Register of Studies (CRS Web), MEDLINE (Ovid, 1946 to July 05, 2019) and LILACS (1982- ). CRS Web includes the Cochrane Epilepsy Group Specialized Register

2019 Cochrane

75. Treatments for seizures in catamenial (menstrual-related) epilepsy. Full Text available with Trip Pro

Treatments for seizures in catamenial (menstrual-related) epilepsy. Catamenial epilepsy describes a worsening of seizures in relation to the menstrual cycle and may affect around 40% of women with epilepsy. Vulnerable days of the menstrual cycle for seizures are perimenstrually (C1 pattern), at ovulation (C2 pattern), and during the luteal phase (C3 pattern). A reduction in progesterone levels premenstrually and reduced secretion during the luteal phase is implicated in catamenial C1 and C3 (...) with regular menses, and complete cessation of menstruation using synthetic hormones (e.g. medroxyprogesterone (Depo-Provera) or gonadotropin-releasing hormone (GnRH) analogues (triptorelin and goserelin)) in women with irregular menses.Catamenial epilepsy and seizure exacerbation is common in women with epilepsy, and may have a significant negative impact on quality of life. Women may not be receiving appropriate treatment for their seizures because of uncertainty regarding which treatment works best

2019 Cochrane

76. CRACKCast E206 – Seizures

with another episode of CRACKCast. Today, we will be covering the topic of seizures. This content is exceedingly important, as approximately 10% of adults will experience at least one seizure. Additionally, 3% of all persons will be diagnosed with epilepsy, thus further reinforcing the importance of knowing this content. Today, we will go about diving into the nitty gritty of seizure disorders, giving you the knowledge to differentiate between neurogenic seizures, psychogenic seizures, and seizure mimics (...) psychogenic seizures when the patient is mid-episode is impossible. Additionally, anywhere from 5-50% of all patients with psychogenic non-epileptic seizures ALSO HAVE EPILEPSY, further complicating treatment, investigation, and disposition of these patients. There are features classically described in the literature that can help you differentiate between psychogenic and neurogenic seizures, and we have listed them in the table below. Just remember, it is not always as clear cut as we would like

2019 CandiEM

77. Lacosamide - epilepsy medicine used to treat partial-onset seizures

) An overview of Lacosamide UCB and why it is authorised in the EU What is Lacosamide UCB and what is it used for? Lacosamide UCB is an epilepsy medicine used to treat partial-onset seizures (epileptic fits starting in one specific part of the brain) in patients with epilepsy aged 4 years or older. It can be used to treat partial-onset seizures with or without secondary generalisation (where the seizure subsequently spreads to other parts of the brain). Lacosamide UCB is given on its own or combined (...) does Lacosamide UCB work? The active substance in Lacosamide UCB, lacosamide, is an epilepsy medicine. Epilepsy is caused by excessive electrical activity in the brain. The exact way in which lacosamide works is still unclear but it seems to reduce the activity of sodium channels (pores on the surface of nerve cells) that allow electrical impulses to be transmitted between nerve cells. This action may prevent abnormal electrical activity in the brain, reducing the chance of an epileptic fit. What

2019 European Medicines Agency - EPARs

78. Laser Interstitial Thermal Therapy for Epilepsy and/or Brain Tumours: A Review of Clinical Effectiveness and Cost-Effectiveness

, medically-intractable temporal lobe epilepsy. Relative to patients who were treated with stereotactic radiosurgery and craniotomy, patients treated with LITT appeared to experience fewer adverse events and complications. No comparative evidence on disease progression, overall survival, hospitalization, or quality of life was found. None of the studies reported on the incidence of epileptic episodes, post-operative pain, use of medication, or hospital readmissions. A Markov model-based economic analysis (...) Laser Interstitial Thermal Therapy for Epilepsy and/or Brain Tumours: A Review of Clinical Effectiveness and Cost-Effectiveness Laser Interstitial Thermal Therapy for Epilepsy and/or Brain Tumours: A Review of Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Laser Interstitial Thermal Therapy for Epilepsy and/or Brain Tumours: A Review of Clinical Effectiveness and Cost-Effectiveness Laser Interstitial Thermal Therapy for Epilepsy and/or Brain Tumours

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

79. Pharmacogenetic testing to identify the risk of adverse reactions to anti-epileptic medications.

Pharmacogenetic testing to identify the risk of adverse reactions to anti-epileptic medications. Pharmacogenetic testing - Health Technology Wales > Pharmacogenetic testing Pharmacogenetic testing Topic Status Complete Pharmacogenetic testing to identify the risk of adverse reactions to anti-epileptic medications. Outcome The evidence on the use of pharmacogenetics testing to identify the risk of adverse reactions to anti-epileptic medications is limited. Some evidence was identified on the use (...) of human leukocyte antigen (HLA) testing to determine whether carbamazepine treatment should be prescribed. However, expert opinion suggests that carbamazepine is no longer offered as first-line treatment and people with newly diagnosed epilepsy are instead offered a drug with a lower rate of adverse drug reactions. As such, this testing approach may be of limited applicability to current practice. The HTW Assessment Group concluded that informed guidance could not be made at this time. Why

2019 Health Technology Wales

80. Sulthiame add-on therapy for epilepsy. Full Text available with Trip Pro

Sulthiame add-on therapy for epilepsy. This is an updated version of the Cochrane Review previously published in the Cochrane Database of Systematic Reviews 2015, Issue 10. Epilepsy is a common neurological condition, characterised by recurrent seizures. Most people respond to conventional antiepileptic drugs, however, around 30% will continue to experience seizures, despite treatment with multiple antiepileptic drugs. Sulthiame, also known as sultiame, is a widely used antiepileptic drug (...) infants with newly diagnosed West syndrome. This trial was funded by DESITIN Pharma, Germany. During the study, sulthiame was given as an add-on therapy to pyridoxine. No data were reported for the outcomes: 50% or greater reduction in seizure frequency between baseline and end of follow-up; mean seizure frequency; or quality of life. For complete cessation of seizures during a nine-day follow-up period for add-on sulthiame versus placebo, the RR was 11.14 (95% CI 0.67 to 184.47; very low-certainty

2019 Cochrane